Companies › MeiraGTx Ocular UK
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Ophthalmology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AAV5-hRKp.RPGR (botaretigene sparoparvovec, JNJ-74765340) AAV5-mediated RPGR gene replacement | RPGR | Phase 3 | Retinitis Pigmentosa; X-Linked Retinitis Pigmentosa | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05926583 | AAV5-hRKp.RPGR (botaretigene sparoparvovec, JNJ-74765340) | Phase 3 | Retinitis Pigmentosa | Ophthalmology | Jun 2027 |
| NCT04794101 | AAV5-hRKp.RPGR (botaretigene sparoparvovec, JNJ-74765340) | Phase 3 | X-Linked Retinitis Pigmentosa | Ophthalmology | Sep 2029 |
| NCT06646289 | AAV5-hRKp.RPGR (botaretigene sparoparvovec, JNJ-74765340) | Phase 2 | X-Linked Retinitis Pigmentosa | Ophthalmology | Oct 2030 |
Beacon Therapeutics Tecnoquimicas Neurotech Pharmaceuticals Innostellar Biotherapeutics jCyte
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.